Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer

• Status: Withdrawn
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether giving an anti-inflammatory medication (corticosteroid) prior to a positron emission tomography scan (PET) scan may reduce or eliminate false findings related to inflammation

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Fluorodeoxyglucose F18; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Patient undergoing initial staging of biopsy proven lung cancer (all cancer stages included)

• Undergone clinical FDG PET/CT scan within 14 days of enrollment

Exclusion Criteria:

• Prisoners

• Diabetic patients (on insulin, on oral hypoglycemic, or fasting glucose > 180 mg/dl)

• Serious infection within 14 days of enrollment

• Known hypersensitivity to methylprednisolone

• Viral skin lesions

• Immunocompromised ANC(absolute neutrophil count < 1000/microliter)

• Pregnant/nursing

• History of tuberculosis or systemic fungal disease

• History of steroid psychosis

• Current peptic ulcer disease or diverticulitis

• Corticosteroid use within 14 days of enrollment (including inhaled steroids)